Bayer CropScience Q1 Results FY27: PAT at Rs 321 Cr for June 2026 Quarter

Bayer CropScience Q1 results FY27: PAT Rs 321 Cr (+15.39% YoY) | Revenue Rs 1,835 Cr (-4.16% YoY) | Gross Margin 17.3% | Stock Rs 4,302.9 (down 0.65%)

The Bayer CropScience Q1 results FY27 show standalone revenue of Rs 1,835 Cr for the quarter ended 30 June 2026, -4.16% year on year from Rs 1,914 Cr in Q1 FY26, as Bayer CropScience reported its numbers on 6 August 2026. Bayer CropScience posted pat of Rs 321 Cr for the quarter, against Rs 278 Cr in Q1 FY26, a change of +15.39%. Shares traded around Rs 4,302.9 on the NSE, down 0.65% on the day.

The June 2026 quarter played out against a broadly stable macro backdrop, contained inflation, a supportive monsoon outlook, and resilient domestic consumption, though global uncertainty around tariffs and commodity prices kept sector-level variability elevated. Against that backdrop, the Bayer CropScience Q1 results FY27 give investors the first hard data point for FY27. This article breaks down what happened at the revenue, gross profit, and net profit line, what the numbers mean for the full year, and what questions investors should be asking before making any portfolio decision.

Click Here – Get Free Investment Predictions

Bayer CropScience Q1 results FY27 Financial Highlights

All figures are standalone numbers in Rs Crore as reported by Bayer CropScience for Q1 FY27 (April to June 2026). The table compares them against the same quarter in FY26.

Bayer CropScience Q1 results FY27 Performance Analysis

Revenue contracted this quarter, the most visible headwind in the numbers. Bayer CropScience reported Rs 1,835 Cr, down -4.16% from Rs 1,914 Cr in Q1 FY26. Investors will want to understand whether this is a cyclical correction, a volume/mix issue, or something more structural.

Gross profit improved faster than revenue. The gross profit came in at Rs 317 Cr (17.3% margin), up -1.15% year on year from Rs 321 Cr. The positive operating jaws confirm that Bayer CropScience is converting its topline growth into margin expansion rather than giving it away on costs.

The bottom line improved alongside the topline. Net profit (pat) reached Rs 321 Cr, up +15.39% from Rs 278 Cr in Q1 FY26. The earnings growth is healthy and broadly consistent with revenue growth, suggesting the business is scaling without sacrificing margin quality.

Check the Univest Screener for Live Data

Bayer CropScience Q1 results FY27: Key Business Factors

1. Revenue: What Drove the Quarter

Bayer CropScience reported revenue of Rs 1,835 Cr for the June 2026 quarter, down -4.16% from Rs 1,914 Cr in Q1 FY26. A revenue decline in the broader market can reflect channel destocking, a strategic exit from low-margin business, or genuine demand weakness. Management’s explanation on the earnings call will determine how investors reprice the stock. Investors should distinguish between structural decline and a one-quarter correction before drawing conclusions from the Bayer CropScience Q1 results FY27.

2. Gross Profit and Margin Trends

Gross margin was broadly stable at 17.3% versus 16.8% in Q1 FY26. Stability in this line is a credible outcome for the broader market, where input cost movements, demand cyclicality and competitive intensity can move margins sharply quarter to quarter. Sustained gross margin stability gives management a predictable base to work from as it invests in growth for the rest of FY27.

3. Net Profit and Earnings Quality

Bayer CropScience posted pat of Rs 321 Cr for the June 2026 quarter, against Rs 278 Cr in Q1 FY26, a change of +15.39%. This bottom line figure is what drives earnings per share and, ultimately, the P/E multiple at which the stock trades. Analysts will now update their FY27 EPS estimates using this Q1 run rate, adjusted for any seasonal factors and guidance management provides on the earnings call.

Bayer CropScience Q1 results FY27 vs Analyst Expectations

Analyst estimates for the Bayer CropScience Q1 results FY27 varied ahead of the announcement. The actual revenue of Rs 1,835 Cr and PAT of Rs 321 Cr now set the benchmark against which FY27 consensus estimates will be revised. When a company beats on both revenue and profit, the stock typically sees buying in the first post-result session. A miss on both tends to trigger selling and downgrades. A mixed print stays range-bound until the earnings call provides clarity. Investors tracking Bayer CropScience should check live analyst verdict updates on the Univest Screener alongside the stock price movement to contextualise the post-result market reaction.

Bayer CropScience Dividend Update

No specific dividend announcement was confirmed as part of the Bayer CropScience Q1 results FY27 snapshot. Most companies declare dividends at the annual board meeting rather than with quarterly results. Investors tracking Bayer CropScience for its dividend yield should check the official NSE or BSE exchange filing, or the Univest Screener, for the latest record date and payout details.

Bayer CropScience Outlook After Q1 results FY27

The Bayer CropScience Q1 results FY27 establish the Q1 FY27 baseline for revenue at Rs 1,835 Cr and PAT at Rs 321 Cr. Whether FY27 ends up as a year of acceleration depends on two variables: whether the decline in revenue sustains through Q2 to Q4, and whether margin trends improve, stabilise, or deteriorate relative to this quarter’s gross profit margin of 17.3% . Management guidance on the earnings call will be the single most important datapoint for updating FY27 forecasts. Investors should also track macroeconomic inputs relevant to the broader market through the rest of the year.

The Q1 FY27 print gives investors a base to work from, but one quarter is rarely enough to conclude a trend. The key follow-up question for Bayer CropScience is whether the Q1 performance was driven by seasonal tailwinds or something more durable. Q2 FY27 results, due around October 2026, will be the first test of that. Investors should also watch for any corporate actions, debt announcements, or management changes in the interim.

Should You Buy Bayer CropScience After the Q1 results FY27?

The question most investors ask after any quarterly result is whether it changes the investment case. The Bayer CropScience Q1 results FY27 show revenue of Rs 1,835 Cr, gross profit of Rs 317 Cr, and PAT of Rs 321 Cr. Whether these numbers justify buying, holding, or selling depends on the price the stock is trading at (Rs 4,302.9 at the time of this result), the FY27 consensus earnings estimate, and whether this Q1 run rate is sustainable for the remaining three quarters. Investors should check the P/E, P/B, and EV/EBITDA multiples on the Univest Screener against sector peers before deciding. This article is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered investment advisor before making any investment decision.

Bayer CropScience Share Price After the Q1 results FY27

Bayer CropScience shares traded at Rs 4,302.9 on the NSE, down 0.65% on the day the Bayer CropScience Q1 results FY27 were in focus. Post-result price moves are often driven by event-driven traders who have built positions ahead of the result and unwind them regardless of outcome. Investors should look past the first-session move and focus on whether the fundamental trend in revenue and earnings has changed. The 52 week high, 52 week low, and technical support levels for Bayer CropScience are available on the Univest Screener for investors who want to time their entry or exit.

Download the Univest iOS App or Univest Android App to track Bayer CropScience live share price and upcoming quarterly results.

Key Risks to Track After the Bayer CropScience Q1 results FY27

Investors should weigh these risks carefully before acting on the Q1 data.

1. Sector and Margin Risk

Bayer CropScience operates in the broader market, which is exposed to input cost movements, demand cyclicality and competitive intensity. A reversal of the trends visible in the Bayer CropScience Q1 results FY27, particularly on the gross profit margin, could put the full-year FY27 earnings estimate at risk.

2. Single-Quarter vs Trend Risk

A single quarterly result can be distorted by working capital cycles, timing of receivables, or one-off costs and reversals that do not repeat. The Bayer CropScience Q1 results FY27 should be read alongside Q2 data before drawing firm conclusions.

3. Macro and External Risk

Macro factors including RBI rate decisions, INR/USD movements, input commodity prices, and rural versus urban demand mix can shift the environment in the broader market faster than company-level actions can compensate for.

Conclusion

Investors researching the Bayer CropScience Q1 results FY27 will find the key numbers, revenue, gross profit, and net profit, summarised in the table above and analysed in each section of this article.

The Bayer CropScience Q1 results FY27 show standalone revenue of Rs 1,835 Cr (-4.16% year on year) and PAT of Rs 321 Cr (versus Rs 278 Cr in Q1 FY26). Gross profit came in at Rs 317 Cr at a margin of 17.3%, declining from Rs 321 Cr a year earlier. A revenue decline and a stronger bottom line were the two key themes of the quarter. Investors tracking Bayer CropScience should use the Bayer CropScience Q1 results FY27 as the baseline and watch Q2 FY27 results, due around October 2026, as the first confirmation of whether these trends are durable. Always consult a SEBI-registered advisor before acting on any quarterly result.

Frequently Asked Questions on Bayer CropScience Q1 results FY27

What were the Bayer CropScience Q1 results FY27?

Ans. Bayer CropScience reported revenue of Rs 1,835 Cr (-4.16% YoY) and PAT of Rs 321 Cr for Q1 FY27 (quarter ended 30 June 2026), against Rs 278 Cr in Q1 FY26.

What is the PAT in the Bayer CropScience Q1 results FY27?

Ans. PAT in the Bayer CropScience Q1 results FY27 stood at Rs 321 Cr, compared with Rs 278 Cr in Q1 FY26, a change of +15.39%.

What was the revenue in the Bayer CropScience Q1 results FY27?

Ans. Revenue in the Bayer CropScience Q1 results FY27 was Rs 1,835 Cr, a change of -4.16% from Rs 1,914 Cr in Q1 FY26.

What was the gross profit in the Bayer CropScience Q1 results FY27?

Ans. Gross profit in the Bayer CropScience Q1 results FY27 was Rs 317 Cr (17.3% margin), compared with Rs 321 Cr in Q1 FY26, a change of -1.15%.

Did Bayer CropScience declare a dividend with the Q1 results FY27?

Ans. No dividend was confirmed as part of the Bayer CropScience Q1 results FY27 snapshot. Check the NSE or BSE exchange filing for the latest dividend announcement from Bayer CropScience.

What is the outlook for Bayer CropScience after Q1 results FY27?

Ans. Following the Bayer CropScience Q1 results FY27, analysts will track whether the decline in revenue and improvement in profit continue into Q2 FY27 (September quarter), along with margin trends and management guidance.

Is Bayer CropScience a good buy after Q1 results FY27?

Ans. The Bayer CropScience Q1 results FY27 show revenue of Rs 1,835 Cr and PAT of Rs 321 Cr. Investment decisions should be based on valuation relative to earnings trajectory, not a single quarter. Consult a SEBI-registered advisor before investing.